Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2020 | Neurovascular dysfunction and Alzheimer’s disease pathology

Costantino Iadecola • 29 Jul 2020
AAIC 2020
Dementia Vascular Dementia

Costantino Iadecola, MD, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, discusses how pathogenic proteins in Alzheimer’s disease, namely tau and amyloid-β, can cause neurovascular dysfunction. Pathogenic factors can impact the brain via both neurons and blood vessels, causing synaptic impairment and inhibiting oxygen and blood flow. Thus, Dr Iadecola concludes that vascular abnormalities are imperative for clinical diagnosis of dementia. This interview was recorded during an online conference with The Video Journal of Dementia (VJDementia).

More from Costantino Iadecola

Vascular abnormalities as a predictive precursor for Alzheimer's disease
1:38
Vascular abnormalities as a predictive precursor for Alzheimer's disease
Costantino Iadecola • 29 Jul 2020
The importance of concordant treatment for Alzheimer's disease and vascular health
1:27
The importance of concordant treatment for Alzheimer's disease and vascular health
Costantino Iadecola • 29 Jul 2020
Atypical presentation of Alzheimer's disease in younger patients
2:09
Atypical presentation of Alzheimer's disease in younger patients
Costantino Iadecola • 29 Jul 2020

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals